Necrotizing granulomatous diseases of the lungs are usually dependent on a narrow range of differential diagnoses. Tuberculosis (TB) is responsible for the largest number of cases, while necrotizing sarcoidosis is generally considered a rare and easily distinguishable disease substantially based on histological features. However, this entity has become a viable diagnosis in the absence of mycobacteria isolation or when a remarkable clinical improvement cannot be achieved with the combination of anti-TB drugs at full dosage. The classic manifestations of TB and sarcoidosis have an overlapping range for which it is sometimes difficult to make a clinical diagnosis. Furthermore, the role of mycobacteria as a trigger antigen capable of evoking the clinical expression of sarcoidosis is a hypothesis supported by evidence from some cases. We report a case of bilateral tuberculous pleurisy in a 45-year-old male native of a North-African region with an atypical severe multisystem disease characterized by a fever resistant to anti-TB therapy and respondent to corticosteroid treatment. The choice to continue both steroid and anti-TB therapy proved to be correct for the late evidence of TB mycobacterial growth only on pleural specimens. The case described is suggestive of a coexistent systemic sarcoid manifestation and low-antigen TB, which is an underrecognized entity in the medical literature.

1.
Chittock DR, Joseph MG, Paterson NA, McFadden RG: Necrotizing sarcoid granulomatosis with pleural involvement. Clinical and radiographic features. Chest 1994;106:672-676.
2.
Moller DR: Treatment of sarcoidosis - from a basic science point of view. J Intern Med 2003;253:31-40.
3.
Drake WP, Newman LS: Mycobacterial antigens may be important in sarcoidosis pathogenesis. Curr Opin Pulm Med 2006;12:359-363.
4.
Fité E, Fernández-Figueras MT, Prats R, Vaquero M, Morera J: High prevalence of Mycobacterium tuberculosis DNA in biopsies from sarcoidosis patients from Catalonia, Spain. Respiration 2006;73:20-26.
5.
Agarwal R, Gupta D: Tuberculous sarcoidosis: is it a separate entity? Lung India 2009;26:61-62.
6.
Ramos-Casals M, Mañà J, Nardi N, Brito-Zeròn P, Xaubet A, Sãnchez-Tapias JM, Cervera R, Font J; HISPAMEC Study Group: Sarcoidosis in patients with chronic hepatitis C virus infection: analysis of 68 cases. Medicine (Baltimore) 2005;84:69-80.
7.
Rosen Y: Four decades of necrotizing sarcoid granulomatosis. What do we know? Arch Pathol Lab Med 2015;139:252-262.
8.
Arfi J, Kerrou K, Traore S, Huchet V, Bolly A, Antoine M, Delaunois L, Vander Borght T, Talbot JN: F-18 FDG PET/CT findings in pulmonary necrotizing sarcoid granulomatosis. Clin Nucl Med 2010;35:697-700.
9.
Wong CF, Yew WW, Wong PC, Lee J: A case of concomitant tuberculosis and sarcoidosis with mycobacterial DNA present in the sarcoid lesion. Chest 1998;114:626-629.
10.
Lin JY, Sheu SJ: Ocular sarcoidosis and tuberculous lymphadenopathy: coincidence or real association. J Ophthal Inflamm Infect 2011;1:137-140.
11.
Bretagne L, Diatta I-D, Faouzi M, Nobile A, Bongiovanni M, Nicod LP, Lazor R: Diagnostic value of the CD103+CD4+/CD4+ ratio to differentiate sarcoidosis from other causes of lymphocytic alveolitis. Respiration 2016;91:486-496.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.